High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer.
Anticancer Res
; 39(9): 5009-5018, 2019 Sep.
Article
de En
| MEDLINE
| ID: mdl-31519608
ABSTRACT
BACKGROUND/AIM:
Interleukin (IL)-18, which belongs to the IL-1 superfamily of cytokines, is a known interferon-gamma (IFN-γ)-inducing factor. Since IFN-γ plays an essential role in anticancer immunity mediated through cytotoxic T cells, IL-18 may also contribute to the function of immunosurveillance. The aim of the study was to examine the association of IL-18 with the outcomes of patients with breast cancer. PATIENTS ANDMETHODS:
Serum IL-18 levels were determined at baseline in 270 patients operated for breast cancer, and the relapse-free survival (RFS) was compared between IL-18-high and -low groups. The relationships between IL-18 and tumor-infiltrating lymphocytes (TILs) or the neutrophil-to-lymphocyte ratio (NLR) were also investigated.RESULTS:
The RFS of patients was significantly better in the IL-18-low group than in the IL-18-high group (p=0.032). According to the multivariate analysis, IL-18 was a significant and independent predictive factor for RFS (hazard ratio(HR)=0.336; 95% confidence interval(CI)=0.147-0.727; p=0.0053). No association was observed between the IL-18 levels and TILs or NLRs.CONCLUSION:
IL-18 levels may be useful for predicting the prognosis of patients who have received surgical treatment for breast cancer.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du sein
/
Marqueurs biologiques tumoraux
/
Interleukine-18
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites:
Female
/
Humans
Langue:
En
Journal:
Anticancer Res
Année:
2019
Type de document:
Article
Pays d'affiliation:
Japon